Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Characterizing and developing ligands for the Huntington disease protein

EF 2024-25

Résumé
Huntington disease (HD) is a genetic neurodegenerative disorder resulting in the progressive loss of motor and cognitive function. The average age of onset is approximately 40 years and the lifespan thereafter averages only 15-20 years. HD is caused by a mutation in a gene that encodes a protein called huntingtin (HTT), which plays important roles in neurological and cellular functions. Despite the HD mutation having been identified over 30 years ago, there are still no disease-modifying treatments for it. This is largely because the exact mechanism behind how the HTT protein works and why the mutated version gives rise to HD is not yet fully understood. This research is currently limited by the lack of available high-quality ligands for the HTT protein. A ligand is a small molecule that can bind and attach to a protein of interest, useful to tag proteins for their quantification and visualization. At the Structural Genomics Consortium (SGC) in Toronto, and in collaboration with various pharmaceutical and research organizations, I seek to evaluate a collection of potential HTT ligands and identify the top-performing compounds. I will evaluate their binding affinity and strength through a highly sensitive technique called surface plasmon resonance (SPR). I will also structurally visualize how they bind to HTT using a high-resolution microscopy technique called cryogenic electron microscopy (Cryo-EM). As these ligands are being characterized, I will use computational software to strategically modify these ligands for improved binding strength and solubility. Once validated, I will share these optimized tools with fellow HD researchers to more effectively uncover the biology of HTT as well as develop HTT-targeting therapeutics for people with HD.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529984
Name
Leung Rocher H
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing and developing ligands for the Huntington disease protein
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biochemistry; Biophysics; Huntington Disease; Pharmacology; Structural Biology
Abstract
Huntington disease (HD) is a genetic neurodegenerative disorder resulting in the progressive loss of motor and cognitive function. The average age of onset is approximately 40 years and the lifespan thereafter averages only 15-20 years. HD is caused by a mutation in a gene that encodes a protein called huntingtin (HTT), which plays important roles in neurological and cellular functions. Despite the HD mutation having been identified over 30 years ago, there are still no disease-modifying treatments for it. This is largely because the exact mechanism behind how the HTT protein works and why the mutated version gives rise to HD is not yet fully understood. This research is currently limited by the lack of available high-quality ligands for the HTT protein. A ligand is a small molecule that can bind and attach to a protein of interest, useful to tag proteins for their quantification and visualization. At the Structural Genomics Consortium (SGC) in Toronto, and in collaboration with various pharmaceutical and research organizations, I seek to evaluate a collection of potential HTT ligands and identify the top-performing compounds. I will evaluate their binding affinity and strength through a highly sensitive technique called surface plasmon resonance (SPR). I will also structurally visualize how they bind to HTT using a high-resolution microscopy technique called cryogenic electron microscopy (Cryo-EM). As these ligands are being characterized, I will use computational software to strategically modify these ligands for improved binding strength and solubility. Once validated, I will share these optimized tools with fellow HD researchers to more effectively uncover the biology of HTT as well as develop HTT-targeting therapeutics for people with HD.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Leung, Rocher H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~